Inventurus Knowledge Solutions Limited has informed the Exchange about Investor Presentation
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IKS Health announced a strategic acquisition of US-listed TruBridge, Inc., a provider of integrated RCM (Revenue Cycle Management) and EHR (Electronic Health Record) solutions for small and rural US hospitals. The deal values TruBridge at $557M enterprise value ($427M equity + $130M net debt) and will be funded through ~$600M of debt at SOFR+275 bps, giving combined leverage of ~3x EBITDA. On a proforma FY2025 basis, the combined entity would have $698M revenue and $186M adjusted EBITDA (26% margin), with management stating the deal will be PAT and EPS accretive in FY27. IKS also unveiled an FY2030 vision targeting EBITDA of ~₹3,000 crore (vs ~₹1,000 crore LTM Dec 2025), implying aggressive scaling. The company highlighted a $575M cross-sell white space in TruBridge's client base and a $650M opportunity for TruCode, expecting close in Q2 FY27.
This is a significant debt-funded expansion that nearly doubles IKS's revenue base and gives it a foothold in the US hospital EHR market. While leverage of ~3x EBITDA increases financial risk, the management's projection of near-term accretion and a 3x EBITDA growth target by FY30 could be a positive catalyst for the stock, provided integration risks are managed well.